- Home
- CMND vs VRAX Comparison
CMND vs VRAX Comparison
Compare CMND & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMND | VRAX |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Canada | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6M | 2.3M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CMND | VRAX |
|---|---|---|
| Price | $1.76 | $2.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 98.4K | ★ 467.8K |
| Earning Date | 03-12-2026 | 06-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $217,274.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.07 | $0.10 |
| 52 Week High | $4.66 | $13.19 |
Technical Indicators
Market Signals| Indicator | CMND | VRAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.45 | 50.09 |
| Support Level | $1.74 | $0.19 |
| Resistance Level | $2.28 | $3.10 |
| Average True Range (ATR) | 0.13 | 0.28 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 37.01 | 13.92 |
Price Performance
Historical ComparisonAbout CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.